



Nanospectra Biosciences, Inc.

8285 El Rio Street, Suite 150
Houston, Texas 77054
(713) 842-2720 ext 201 Fax (713) 440-9349

For Immediate Release

Nanospectra Biosciences Closes on \$1.5 Million in Additional Series A Preferred Stock

Funds Devoted to Clinical Development of AuroLase™ Cancer Therapy

Houston, Texas – January 5, 2009 – Nanospectra Biosciences, Inc. today announced that it recently closed on an additional \$1.5 million of Series A Preferred Stock placed with its existing investors. The proceeds will fund the continued clinical trial of AuroLase™ cancer therapy in head and neck cancer and IDE-enabling work on additional cancer indications.

“We are pleased that our existing investors showed strong support for our progress,” stated J. Donald Payne, President and CEO of Nanospectra Biosciences. “We have very exciting preclinical data in other cancer indications and we will be moving these applications forward as the head and neck trial progresses.”

About Nanospectra Biosciences:

Nanospectra Biosciences, Inc. is a privately held, emerging life science company engaged in the commercialization of AuroLase™ Therapy, a particle-based therapy for the selective and precise thermal destruction of solid tumors while minimizing damage to healthy adjacent tissue and preserving critical structures. AuroLase Therapy is an investigational medical device currently being evaluated in a clinical study. Based in Houston, Texas, the Company was founded on intellectual property from Rice University and collaborative research with scientists at MD Anderson Cancer Center.

For further information, contact:

Nanospectra Biosciences, Inc.
J. Donald Payne
(713) 842-2720 ext 201
DPayne@Nanospectra.com
www.Nanospectra.com